• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

作者信息

Autio Karen A, McHugh Deaglan J, Rathkopf Dana E, Xiao Han, Merugu Swathi, Wong Phillip, Jan Mehrin, Dorff Tanya B, Heath Elisabeth I, Scher Howard I

机构信息

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Weill Cornell Medical College, New York, NY, USA.

出版信息

J Immunother Precis Oncol. 2025 Apr 23;8(2):172-176. doi: 10.36401/JIPO-24-36. eCollection 2025 May.

DOI:10.36401/JIPO-24-36
PMID:40270785
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12010483/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/e8308e4a92fd/10.36401_JIPO-24-36-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/20e1a52e4173/10.36401_JIPO-24-36-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/e8308e4a92fd/10.36401_JIPO-24-36-f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/20e1a52e4173/10.36401_JIPO-24-36-f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/e8308e4a92fd/10.36401_JIPO-24-36-f02.jpg

相似文献

1
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.奥拉帕利和度伐利尤单抗用于DNA损伤修复改变和生化复发前列腺癌患者的研究
J Immunother Precis Oncol. 2025 Apr 23;8(2):172-176. doi: 10.36401/JIPO-24-36. eCollection 2025 May.
2
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.度伐利尤单抗联合卡铂/紫杉醇，随后使用度伐利尤单抗联合或不联合奥拉帕利作为新诊断的晚期或复发性子宫内膜癌的一线治疗：III期DUO-E试验的日本亚组分析
J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118.
3
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.度伐利尤单抗联合奥拉帕利治疗伴有和不伴有 DNA 损伤修复突变的转移性去势抵抗性前列腺癌男性患者的疗效。
J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.
4
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
5
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.精准医学 II 期研究评估了度伐利尤单抗和替西木单抗联合奥拉帕利在接受奥拉帕利治疗有反应或稳定的固体瘤和同源重组修复基因突变携带者中的疗效。
BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
6
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.奥拉帕利单药治疗或与阿比特龙联合用于治疗转移性去势抵抗性前列腺癌（mCRPC）且存在BRCA突变的患者。
Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.
7
PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.聚（ADP-核糖）聚合酶（PARP）抑制剂奥拉帕利可诱导DNA损伤，并在犬类造血癌的体外模型中作为一种药物增敏剂发挥作用。
BMC Vet Res. 2025 Jul 5;21(1):439. doi: 10.1186/s12917-025-04880-z.
8
Olaparib for the treatment of metastatic prostate cancer.奥拉帕利治疗转移性前列腺癌。
Future Oncol. 2021 Jul;17(19):2413-2429. doi: 10.2217/fon-2020-1245. Epub 2021 Mar 26.
9
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.PARP 抑制剂在 HRR 突变的 mCRPC 二线治疗中的疗效和安全性：系统评价和贝叶斯网络荟萃分析。
BMC Cancer. 2024 Jun 8;24(1):706. doi: 10.1186/s12885-024-12388-2.
10
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.一项 PD-L1 抑制剂 durvalumab 联合 PARP 抑制剂 olaparib 和 VEGFR1-3 抑制剂 cediranib 治疗有生物标志物分析的复发性女性癌症的 I 期研究。
J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

本文引用的文献

1
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.奥拉帕利治疗前列腺癌术后生化复发高危患者的疗效：一项非随机对照试验
JAMA Oncol. 2024 Oct 1;10(10):1400-1408. doi: 10.1001/jamaoncol.2024.3074.
2
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).鲁卡帕尼单药治疗非转移性、激素敏感性前列腺癌的II期研究，显示“BRCA样”基因型（ROAR）。
Oncologist. 2024 May 3;29(5):450-e725. doi: 10.1093/oncolo/oyae030.
3
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
4
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.芦卡帕利或医生选择治疗转移性前列腺癌。
N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16.
5
Therapeutic targeting of tumour myeloid cells.肿瘤髓样细胞的治疗靶点
Nat Rev Cancer. 2023 Apr;23(4):216-237. doi: 10.1038/s41568-022-00546-2. Epub 2023 Feb 6.
6
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.晚期前列腺癌患者的管理。第一部分：中高危和局部进展性疾病、生化复发和激素治疗的副作用：2022 年晚期前列腺癌共识会议报告。
Eur Urol. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6.
7
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis.循环髓系来源抑制细胞与前列腺癌患者的生存率：系统评价与荟萃分析。
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):41-46. doi: 10.1038/s41391-022-00615-5. Epub 2022 Nov 21.
8
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.醋酸阿比特龙联合泼尼松、地加瑞克或二者联合用于根治性前列腺切除术后生化复发前列腺癌男性患者的随机2期试验。
Eur Urol Open Sci. 2021 Nov 17;34:70-78. doi: 10.1016/j.euros.2021.09.015. eCollection 2021 Dec.
9
The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.免疫疗法在生化复发前列腺癌中的潜在作用。
Urol Clin North Am. 2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004.
10
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌的生存获益。
N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.